A Phase Study of PHN-012 in Patients With Advanced Solid Tumors

The primary objective of this study is to evaluate the clinical activity of PHN-012 in patients diagnosed with advanced solid tumors. This investigation aims to determine the potential therapeutic benefit in a population where standard treatment options may be limited. No secondary objectives were specified.

The study population consists of 115 patients with advanced solid tumors. The cohort includes both male and female participants. Based on the age range codes provided, the subjects fall within specific age categories. The sponsor did not provide information regarding lifestyle considerations or selection methodologies.

This Phase 1 clinical trial is designed to evaluate PHN-012 in individuals diagnosed with advanced solid tumors. The study follows a specific research methodology to assess the safety and efficacy of the investigational product. The protocol commences with a screening visit to determine eligibility based on predefined criteria. Following successful enrollment, participants undergo scheduled follow-up visits to monitor clinical responses and potential adverse effects. The clinical sequence concludes with an end-of-study visit. The total duration of the trial is estimated to span from April 2026 to May 2028. Participation may be discontinued prior to the completion of the scheduled protocol if specific clinical conditions necessitate early termination.

The assessment of efficacy in this Phase 1 clinical trial involves the evaluation of therapeutic response in patients diagnosed with advanced solid tumors.